Oxidants, antioxidants and the current incurability of metastatic cancers
Author(s) -
Jim Watson
Publication year - 2013
Publication title -
open biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.078
H-Index - 53
ISSN - 2046-2441
DOI - 10.1098/rsob.120144
Subject(s) - biology , mesenchymal stem cell , metformin , cancer research , reactive oxygen species , drug , cancer , pharmacology , bioinformatics , microbiology and biotechnology , diabetes mellitus , endocrinology , genetics
The vast majority of all agents used to directly kill cancer cells (ionizing radiation, most chemotherapeutic agents and some targeted therapies) work through either directly or indirectly generating reactive oxygen species that block key steps in the cell cycle. As mesenchymal cancers evolve from their epithelial cell progenitors, they almost inevitably possess much-heightened amounts of antioxidants that effectively block otherwise highly effective oxidant therapies. Also key to better understanding is why and how the anti-diabetic drug metformin (the world's most prescribed pharmaceutical product) preferentially kills oxidant-deficient mesenchymal p53 − − cells. A much faster timetable should be adopted towards developing more new drugs effective against p53 − − cancers.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom